|
|
||||||||
EDITORIALS
Eric J. Sorenson
| You have reached the most complete version of this article accessible without further authentication.
More complete versions are available. Link to article |
Related Article
This article has been cited by other articles:
![]() |
K. R. Wagner The need for biomarkers in amyotrophic lateral sclerosis drug development Neurology, January 6, 2009; 72(1): 11 - 12. [Full Text] [PDF] |
||||
![]() |
N. Y. Harel, E. J. Sorenson, R .G. Miller, W .G. Bradley, M . Cudkowicz, V . Meininger, H . Mitsumoto, D .H. Moore, V . Silani, M . Strong, et al. WHAT IS NEXT IN ALS CLINICAL TRIALS? Neurology, April 15, 2008; 70(16): 1365 - 1366. [Full Text] [PDF] |
||||
![]() |
A. Hoke, E. J. Sorenson, R .G. Miller, W .G. Bradley, M . Cudkowicz, V . Meininger, H . Mitsumoto, D .H. Moore, V . Silani, M . Strong, et al. WHAT IS NEXT IN ALS CLINICAL TRIALS? Neurology, April 15, 2008; 70(16): 1366 - 1367. [Full Text] [PDF] |
||||
Read all Correspondence
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||